# Study of the Safety and Efficacy of Roxadustat in the Treatment of Heart Failure With Chronic Kidney Disease and Anemia

Study · id `cardio:ct-nct05691257` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05691257](<https://clinicaltrials.gov/study/NCT05691257>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05691257

Browse, organ or system: Heart; Kidneys  
Browse, condition area: Heart failure; Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

## Technical summary

Registry record NCT05691257. Non-randomized; no masking; primary purpose treatment. Start 2023-02-01 (anticipated); primary completion 2023-08-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT05691257, source copy `cardio:ctgov-nct05691257-2023-01-20`, retrieved 2026-10-26)
- Planned start: 2023-02-01 (anticipated) (ClinicalTrials.gov record NCT05691257, source copy `cardio:ctgov-nct05691257-2023-01-20`, retrieved 2026-10-26)
- Primary completion: 2023-08-01 (anticipated) (ClinicalTrials.gov record NCT05691257, source copy `cardio:ctgov-nct05691257-2023-01-20`, retrieved 2026-10-26)
- Completion: 2023-12-01 (anticipated) (ClinicalTrials.gov record NCT05691257, source copy `cardio:ctgov-nct05691257-2023-01-20`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05691257-2023-01-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of the Safety and Efficacy of Roxadustat in the Treatment of Heart Failure With Chronic Kidney Disease and Anemia
- Condition: Heart Failure
- Condition: Chronic Kidney Diseases
- Condition: Anemia
- Intervention (Drug): Roxadustat
- Intervention (Drug): Recombinant human eythropoietin and/or Iron agents
- Lead sponsor: China-Japan Friendship Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: China-Japan Friendship Hospital (`cardio:org-china-japan-friendship-hospital`)

## Provenance

Content hash: ee1923b3d341824af7b101f9e4e6c4f3d955f83526877258328e2e4d1cd0f4ab
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
